A class action lawsuit has been filed against ADMA Biologics, alleging the company failed to disclose an undisclosed related party transaction, engaged in channel stuffing to inflate revenue, and lacked proper internal controls. The lawsuit covers securities purchased between August 2024 and March 2026. The claims follow a report by Culper Research revealing discrepancies in ADMA's reported growth and actual sales, which caused the stock price to drop significantly in March 2026. Investors affected are encouraged to contact the law firm before the August 10, 2026 deadline to join the case.
A shareholder class action lawsuit has been filed against ADMA Biologics, alleging the company made false and misleading statements and failed to disclose key adverse facts. The claims include undisclosed related party transactions, channel stuffing ...
ADMA Biologics and some executives face a securities fraud lawsuit alleging they misled investors by inflating revenue through excess shipments of their product ASCENIV and hiding a related-party distribution deal. The truth surfaced after a report i...
ADMA Biologics is under investigation by Bleichmar Fonti & Auld LLP for allegedly inflating its 2025 revenue growth through channel stuffing, a practice where excess product is pushed to distributors to boost sales figures artificially. Culper Resear...
